Advertisement

Uterine Cancer pp 217-222 | Cite as

Treatment of Advanced and Recurrent Carcinoma

Hormonal Therapy
  • Franco MuggiaEmail author
  • Stephanie V. Blank
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

Progestins were the first drugs to be used in systemic therapy of endometrial cancer. After four decades of clinical trials, their role has been narrowed to a relatively small percentage of tumors that have metastasized but are well differentiated and rich in hormonal receptors. Nevertheless, with better selection of patients likely to benefit from hormonal therapy and the exploration of potential role after chemotherapy, one may look forward to new directions of interest.

Keywords

Endometrial cancer Progestins Hormone receptors 

References

  1. 1.
    Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Eng J Med 1961; 264:216–8.CrossRefGoogle Scholar
  2. 2.
    Kelley RM, Baker WH. The role of progesterone in human endometrial cancer. Cancer Res 1965; 25:1190–2.PubMedGoogle Scholar
  3. 3.
    Taylor RW. In Endometrial Cancer–International Symposium Marburg 1986 – K-D Schulz, RJB King, K Pollow, and RW Taylor, Editors. Treatment of disseminated, recurrent endometrial cancer with progestational agents. W Zuckscherdt Verlag, Munchen, 1987. pp. 155–6.Google Scholar
  4. 4.
    Reifenstein EC. The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. Gynecol Oncol 1974; 2: 377–414.PubMedCrossRefGoogle Scholar
  5. 5.
    Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736–44.PubMedGoogle Scholar
  6. 6.
    Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19(2):364–7.PubMedGoogle Scholar
  7. 7.
    Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 (1): 4–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: Gynecologic Oncology Group study. Gynecol Oncol 2004; 92 (1): 10–14.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Medical Oncology, NYU Cancer Institute, NYU Medical CenterNew York

Personalised recommendations